Blood Pressure Profile and N-Terminal-proBNP Dynamics in Response to Intravenous Methylprednisolone Pulse Therapy of Severe Graves' Orbitopathy.
Piotr MiśkiewiczJustyna Milczarek-BanachTomasz BednarczukGrzegorz OpolskiRenata GlowczynskaPublished in: International journal of molecular sciences (2018)
Hypercortisolemia is associated with increased risk of hypertension. Natural and synthetic glucocorticoids (GCs) have different effects on blood pressure (BP). The effect of synthetic GCs on BP depends on the dose, treatment duration, type of GCs, and route of administration. Intravenous methylprednisolone (IVMP) pulse therapy is the first line of treatment for severe Graves' orbitopathy (GO). The aim of this study was to evaluate influence of IVMP pulses on BP and N-terminal pro-brain natriuretic peptide (NT-proBNP) dynamics. A total of 32 patients with GO were treated with one IVMP pulse every week for 12 weeks. We performed 48-h BP monitoring (24-h before and 24-h after IVMP) and measured NT-proBNP before, 24 h, and 48 h after the 1st, 6th, and 12th IVMP pulse. Mean BP did not change after any of the pulses. We did not observe an increase in maximal systolic BP or mean nocturnal BP, except after the last pulse. Additionally, the dipping phenomenon was less frequent after the last pulse. We found a significant increase in median NT-proBNP levels after all analyzed pulses. Our study suggests that IVMP may have an unfavorable cumulative effect on BP. Variation in NT-proBNP concentration indicates a compensatory effect of brain natriuretic peptide secretion.
Keyphrases
- blood pressure
- hypertensive patients
- heart rate
- high dose
- white matter
- heart failure
- early onset
- clinical trial
- stem cells
- multiple sclerosis
- randomized controlled trial
- obstructive sleep apnea
- weight loss
- metabolic syndrome
- combination therapy
- body composition
- blood brain barrier
- insulin resistance
- depressive symptoms
- bone marrow
- preterm birth
- brain injury
- subarachnoid hemorrhage